Actively Recruiting

Phase Not Applicable
Age: 18Years - 95Years
All Genders
NCT06107504

Prevention of Post-sphincterotomy Bleeding

Led by National Cheng-Kung University Hospital · Updated on 2025-05-25

120

Participants Needed

1

Research Sites

82 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Background and Aim: Endoscopic retrograde cholangiopancreatography (ERCP) and sphincterotomy (EST) are standard treatments for choledocholithiasis. However, 10% of post-EST bleeding was reported. Currently, there are no effective methods or medications for the prevention of post-EST bleeding. This study aimed to investigate whether the local administration of TXA and sucralfate can reduce the post-EST bleeding event. Methods: This is a randomized clinical trial. Patients with choledocholithiasis scheduled for ERCP with EST at National Cheng Kung University Hospital and Siriraj Hospital were enrolled. The study will recruit 120 patients. After randomization, 60 patients will be classified into the intervention group and 60 into the control group. The participants will receive standard ERCP and EST for common bile duct stone removal. If immediate polypectomy bleeding occurs, the investigators will apply standard endoscopic therapy by either local injection of diluted epinephrine or heater probe coagulation. After then, the investigators will spray 2g of sucralfate powder and 1g of tranexamic acid through duodenoscopy precisely on the post-EST wound in the intervention group. All enrolled patients will be monitored for delayed bleeding for 14 days after the ERCP.

CONDITIONS

Official Title

Prevention of Post-sphincterotomy Bleeding

Who Can Participate

Age: 18Years - 95Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged 60; 18 years who accept ERCP and sphincterotomy for common bile duct (CBD) stone extraction
Not Eligible

You will not qualify if you...

  • Patients not scheduled for sphincterotomy
  • Patients with unsuccessful common bile duct cannulation
  • Patients allergic to sucralfate

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

National Cheng-Kung University Hospital

Tainan, Other (Non U.s.), Taiwan, 704

Actively Recruiting

Loading map...

Research Team

H

Hsueh-Chien Chiang, M.D.

CONTACT

X

Xi-Zhang Lin, M.D.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here